Scholarlink

Background <p>The fibrinogen-to-albumin ratio (FAR) has been explored for its role in predicting non-small cell lung cancer (NSCLC) prognosis, but findings remain inconsistent. This study aimed to determine the exact impact of FAR on predicting NSCLC prognosis through a meta-analysis.</p> Methods <p>This study conducted a comprehensive search of PubMed, Web of Science, Embase, Cochrane Library, and CNKI up to April 2, 2025, and determined pooled hazard ratios (HRs) and 95% confidence intervals (CIs) to evaluate the prognostic value of FAR in NSCLC.</p> Results <p>This meta-analysis included seven studies with a total of 2,655 cases. The pooled analysis revealed that an elevated FAR significantly predicted poor overall survival (OS) (HR = 1.82, 95% CI = 1.56–2.14, <i>p</i> &lt; 0.001) and poor progression-free survival (PFS) (HR = 1.50, 95% CI = 1.29–1.74, <i>p</i> &lt; 0.001) in patients with NSCLC, which was strongly associated with male sex (OR = 1.53, 95% CI = 1.12–2.08, <i>p</i> = 0.008) and tumor size ≥ 5&#xa0;cm (OR = 1.52, 95% CI = 1.08–2.14, <i>p</i> = 0.017). However, FAR showed no significant correlation with smoking history (OR = 1.44, 95% CI = 0.80–2.59, <i>p</i> = 0.218) or Eastern Cooperative Oncology Group performance status (OR = 1.60, 95% CI = 0.74–3.45, <i>p</i> = 0.230).</p> Conclusion <p>This meta-analysis suggests that elevated FAR is a strong predictor of OS and PFS in patients with Chinese NSCLC and correlates with larger tumor size.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic and clinicopathological value of fibrinogen-to-albumin ratio in non-small cell lung cancer: a meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月16日

查看全文
  • Ling Tong,
  • Hui Hu,
  • Jiashan Li,
  • Lihai Pan

摘要

Background

The fibrinogen-to-albumin ratio (FAR) has been explored for its role in predicting non-small cell lung cancer (NSCLC) prognosis, but findings remain inconsistent. This study aimed to determine the exact impact of FAR on predicting NSCLC prognosis through a meta-analysis.

Methods

This study conducted a comprehensive search of PubMed, Web of Science, Embase, Cochrane Library, and CNKI up to April 2, 2025, and determined pooled hazard ratios (HRs) and 95% confidence intervals (CIs) to evaluate the prognostic value of FAR in NSCLC.

Results

This meta-analysis included seven studies with a total of 2,655 cases. The pooled analysis revealed that an elevated FAR significantly predicted poor overall survival (OS) (HR = 1.82, 95% CI = 1.56–2.14, p < 0.001) and poor progression-free survival (PFS) (HR = 1.50, 95% CI = 1.29–1.74, p < 0.001) in patients with NSCLC, which was strongly associated with male sex (OR = 1.53, 95% CI = 1.12–2.08, p = 0.008) and tumor size ≥ 5 cm (OR = 1.52, 95% CI = 1.08–2.14, p = 0.017). However, FAR showed no significant correlation with smoking history (OR = 1.44, 95% CI = 0.80–2.59, p = 0.218) or Eastern Cooperative Oncology Group performance status (OR = 1.60, 95% CI = 0.74–3.45, p = 0.230).

Conclusion

This meta-analysis suggests that elevated FAR is a strong predictor of OS and PFS in patients with Chinese NSCLC and correlates with larger tumor size.